TIGIT and cancer: We also analyzed the immune checkpoint-related genes (PD-1, PD-L1, CTLA4, CD86, LAG3, HAVCR2, TIGIT) and HLA family-related genes levels, which are considered biomarkers for predicting the efficacy of immunotherapy, between L_cancer and R_cancer patients and found that the expression levels of immune checkpoint-related genes and HLA family-related genes were significantly higher in R_cancer patients (Wilcoxon test, all P < 0.05; Fig. 3C, D).